Blarcamesine Anavex (blarcamesine)
- Region
- 🇪🇺 EU
- Active substance
- blarcamesine
- Status
- Application withdrawn
- CHMP opinion
- Thu 11 Dec 2025
- Application
- EMEA/H/C/006475
- ATC
- N06D
- Official record
- www.ema.europa.eu
Indication
Treatment of Alzheimer’s disease and dementia.
Regulatory milestones
Wed 25 Mar 2026🇪🇺 Application withdrawn (EU)
Blarcamesine Anavex (blarcamesine): EU application withdrawn
· source
Mon 16 Feb 2026🇪🇺 Expected EC decisionestimate
Blarcamesine Anavex (blarcamesine): expected EC decision
Estimated as CHMP opinion (2025-12-11) + 67 days, the standard Commission decision period. Not an official date. · source
Thu 11 Dec 2025🇪🇺 CHMP positive opinion
Blarcamesine Anavex (blarcamesine): CHMP positive opinion
· source
Follow Blarcamesine Anavex
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.